A first-of-its-kind flu shot is one step closer to being available to the public after a Food and Drug Administration (FDA) advisory panel voted Thursday to recommend Moderna’s mRNA-based vaccine for approval. The FDA’s independent vaccine advisors voted unanimously 9-0 that the benefits outweigh the risks for Moderna’s mFlusiva shot in people ages 50 to 64 as well as 65 and older. Moderna is...
A first-of-its-kind flu shot is one step closer to being available to the public after a Food and Drug Administration (FDA) advisory panel voted Thursday to recommend Moderna’s mRNA-based vaccine for approval. The FDA’s independent vaccine advisors voted unanimously 9-0 that the benefits outweigh the risks for Moderna’s mFlusiva shot in people ages 50 to 64 as well as 65 and older. Moderna is...
<iframe src="https://statesidedaily.com/embed/cluster/220913098a3293c11c683555b616403f2a6908fa" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="FDA panel recommends mRNA flu vaccine for older adults"></iframe>
